NICE Recommends Lebrikizumab for Moderate to Severe AD in the NHS England
The National Institute for Health and Care Excellence (NICE) now recommends lebrikizumab (Ebglyss, Almirall S.A.) for use in moderate to severe atopic dermatitis (AD) in the NHS England. The interleukin-13 blocker is indicated for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with […]